FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Fate Therapeutics
Center for International Blood and Marrow Transplant Research
AvenCell Therapeutics, Inc.
Incyte Corporation
Allogene Therapeutics
Ossium Health, Inc.
Ossium Health, Inc.
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Center for International Blood and Marrow Transplant Research
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
University of Arizona
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Cancer Trials Ireland
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Affiliated Hospital of Nantong University
Universitätsklinikum Hamburg-Eppendorf
Celgene
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
University of Nebraska
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
St. Jude Children's Research Hospital
University of Alabama at Birmingham
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center